Nephrology — Therapeutic Area Intelligence | Humanexa Signals

ClinicalAugust 1, 2026

Novel microRNA Biomarker Approach for Renal Osteodystrophy Treatment

A study is investigating a microRNA approach as a non-invasive biomarker for assessing bone turnover in renal osteodystrophy.

ClinicalJuly 31, 2026

Combination of Rituximab and Cyclosporine in Membranous Nephropathy Trial Initiated

A clinical trial is underway to evaluate the safety and effectiveness of combining rituximab and cyclosporine for treating membranous nephropathy.

ClinicalJuly 29, 2026

Sodium Bicarbonate Shows Promise in Severe Metabolic Acidosis with Acute Kidney Injury

A recent trial indicates that sodium bicarbonate infusion may improve survival rates in patients with severe metabolic acidosis and acute kidney injury.

RegulatoryJuly 28, 2026

FDA Approval Process Update for Tolvaptan by Alkem Labs

The FDA has received an application (ANDA220147) for Tolvaptan from Alkem Labs, currently under standard review.

ClinicalJuly 27, 2026

Roxadustat Study for Anemia in Children with Chronic Kidney Disease Initiated by Astellas Pharma

Astellas Pharma is conducting a study to evaluate the efficacy of roxadustat in treating anemia in children and teenagers with chronic kidney disease, with a duration of up to 52 weeks.

RegulatoryJuly 26, 2026

FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)

The FDA has accepted a supplemental NDA for Filspari (Sparsentan) from Travere.

StrategyJuly 25, 2026

FDA Grants Approval for Teva's Tolvaptan ANDA216933

Teva Pharmaceuticals has received an approval for their Abbreviated New Drug Application (ANDA216933) for Tolvaptan.

ClinicalJuly 24, 2026

Study on Thyroid Hormones in Severe CKD Stages G4-G5 Initiated

A retrospective observational study is evaluating thyroid hormone profiles in patients with severe chronic kidney disease, including those with and without Autosomal Dominant Polycystic Kidney Disease.

ClinicalJuly 23, 2026

Exosomes in Renal Fibrosis: Dual Roles and Therapeutic Potential

Exosomes play a dual role in renal fibrosis, acting as both pro-fibrotic drivers and anti-fibrotic protectors, depending on their origin.

ClinicalJuly 23, 2026

Study on PIIINP and Urinary NGAL as Biomarkers for Renal Function Recovery

The study investigates PIIINP and urinary NGAL as potential biomarkers for predicting progression from Acute Renal Failure to Chronic Renal Failure.

ClinicalJuly 22, 2026

VExUS Protocol Study Aims to Improve Hemodialysis Patient Outcomes

A multicenter study is assessing the VExUS protocol's effectiveness for dry-weight adjustment in hemodialysis patients.

ClinicalJuly 21, 2026

Machine Learning Model Developed to Differentiate Diabetic Kidney Disease in Type 2 Diabetes

A machine learning model has been developed to differentiate diabetic kidney disease from non-diabetic kidney disease in type 2 diabetes patients.

ClinicalJuly 20, 2026

Phase I Trial of VC005 Tablets in Renal Impairment Shows Safety and Pharmacokinetics

A Phase I trial is underway to assess the pharmacokinetics and safety of VC005 tablets in subjects with renal impairment.

ClinicalJuly 19, 2026

Renibus Therapeutics initiates long-term study of Veverimer for CKD and metabolic acidosis

Renibus Therapeutics is conducting a 264-week study to assess the efficacy and safety of Veverimer in adults with moderate-to-severe CKD and metabolic acidosis.

ClinicalJuly 18, 2026

Akebia Therapeutics initiates Phase 2 trial of praliciguat for FSGS

Akebia Therapeutics is conducting Phase 2 trial to assess praliciguat's efficacy and safety in FSGS patients.

ClinicalJuly 18, 2026

Shionogi's S-892216 Study Targets Renal Impairment Pharmacokinetics

A study is underway to assess the pharmacokinetics, safety, and tolerability of S-892216 in patients with varying degrees of renal impairment.

RegulatoryJuly 18, 2026

Novartis Fabhalta® (iptacopan) gains FDA approval for primary IgAN treatment

Fabhalta® (iptacopan) is the first and only complement inhibitor approved by the FDA to significantly slow kidney function decline in primary IgA nephropathy (IgAN).

ClinicalJuly 15, 2026

Otsuka initiates trial for Sibeprenlimab in IgA Nephropathy

Otsuka Pharmaceutical is conducting a trial to evaluate the efficacy and safety of Sibeprenlimab in patients with IgA Nephropathy.

ClinicalJuly 15, 2026

Lactiplantibacillus plantarum WJL enhances low-protein diet efficacy in chronic kidney disease

Lactiplantibacillus plantarum WJL supplementation improved metabolic outcomes in CKD patients on a low-protein diet.

ClinicalJuly 15, 2026

Novartis initiates Phase III trial of Atrasentan in pediatric IgAN patients

Novartis is conducting Phase III trial to evaluate the efficacy and safety of Atrasentan in pediatric patients with primary IgAN.

RegulatoryJuly 15, 2026

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

The FDA has granted Priority Review for Gazyva/Gazyvaro based on phase III MAJESTY results showing significant remission rates in primary membranous nephropathy.

RegulatoryJuly 15, 2026

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

The FDA has granted Priority Review for Gazyva/Gazyvaro based on phase III MAJESTY results showing superior remission rates in primary membranous nephropathy.

ClinicalJuly 13, 2026

Study on Plasma Exchange vs. Daratumumab for Light Chain Cast Nephropathy

A clinical trial is underway to evaluate the effectiveness of plasma exchange compared to daratumumab-based and non-daratumumab-based regimens in improving renal outcomes for patients with light chain cast nephropathy.

ClinicalJuly 11, 2026

Nanotechnology Advances in Podocyte Injury Repair for Chronic Kidney Diseases

Nanotechnology shows promise in repairing podocyte injury, a key factor in chronic kidney diseases, through targeted drug delivery and other mechanisms.

RegulatoryJuly 8, 2026

FDA Approves Trutakna for Proteinuria in Primary IgA Nephropathy

The FDA has approved Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary IgA nephropathy.

ClinicalJuly 8, 2026

Study on AVA Use in Continuous Renal Replacement Therapy to Reduce Catheter Risks

A study will assess the feasibility of using existing arteriovenous access for continuous renal replacement therapy in critically ill patients.

ClinicalJuly 6, 2026

Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients

A study is underway to evaluate the effects of felzartamab on isolated microvascular inflammation in kidney transplant recipients.

StrategyJuly 5, 2026

FDA Accepts ANDA for Tolvaptan by Alkem Labs

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Tolvaptan submitted by Alkem Labs.

ClinicalJune 30, 2026

Phase 1 Study of MTX-439 in Diabetic Kidney Disease Patients Initiated by Mediar Therapeutics

Mediar Therapeutics has initiated Phase 1 trial to evaluate the safety and pharmacokinetics of MTX-439 in healthy adults and those with diabetic kidney disease.

ClinicalJune 29, 2026

Trial on pHA130 Hemoadsorption in Kidney Failure Patients Shows Potential for Improved Outcomes

A randomized controlled trial is evaluating the efficacy of the pHA130 hemoadsorption cartridge in enhancing the removal of protein-bound uremic toxins in maintenance hemodialysis patients.

ClinicalJune 25, 2026

Boehringer Ingelheim Tests Vicadrostat with Empagliflozin in CKD Patients

A clinical trial is underway to evaluate the efficacy of vicadrostat combined with empagliflozin in adults with chronic kidney disease.

ClinicalJune 25, 2026

Amino Acid Infusion Shows No Benefit for AKI Post-Aortic Surgery, Subgroup Suggests Potential in Older Patients

A multicenter study found no significant benefit of amino acid infusion on AKI incidence post-aortic surgery, though older patients showed a potential lower risk.

ClinicalJune 25, 2026

Study Evaluates Nephrotoxic Risks in CKD Patients Using SGLT2 Inhibitors

The study highlights the nephrotoxic medication burden in CKD patients on SGLT2 inhibitors, raising concerns about drug-related problems.

ClinicalJune 23, 2026

SP16 Trial Aims to Prevent Acute Kidney Injury in CKD Patients Undergoing Cardiac Surgery

A clinical trial is underway to evaluate the efficacy and safety of SP16 in preventing acute kidney injury in patients with chronic kidney disease undergoing cardiac surgery.

ClinicalJune 22, 2026

Nalfurafine Hydrochloride Shows Promise for Treating Pruritus in Hemodialysis Patients

A multi-center clinical study is evaluating the efficacy and safety of nalfurafine hydrochloride in treating pruritus in hemodialysis patients over 12 weeks.

ClinicalJune 21, 2026

Pilot Trial of Low-Dose Colchicine in CKD Aims to Improve Vascular and Bone Outcomes

A pilot trial is assessing the efficacy of low-dose colchicine in improving vascular disease and biomarkers in CKD stage 3 patients.

ClinicalJune 20, 2026

Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients

A clinical trial is evaluating the efficacy of ravulizumab in reducing delayed graft function (DGF) in kidney transplant patients.

ClinicalJune 18, 2026

Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults

A clinical trial is underway to evaluate the effects of felzartamab on proteinuria in adults with IgAN.

ClinicalJune 16, 2026

Ultomiris meets primary endpoint in Phase III trial for IgAN

Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.

RegulatoryJune 10, 2026

FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE

The FDA has accepted a supplemental application for FILSPARI (SPARSENTAN) from TRAVERE.

Companies

Assets

Recent signals(40)

Novel microRNA Biomarker Approach for Renal Osteodystrophy Treatment

Combination of Rituximab and Cyclosporine in Membranous Nephropathy Trial Initiated

Sodium Bicarbonate Shows Promise in Severe Metabolic Acidosis with Acute Kidney Injury

FDA Approval Process Update for Tolvaptan by Alkem Labs

Roxadustat Study for Anemia in Children with Chronic Kidney Disease Initiated by Astellas Pharma

FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)

FDA Grants Approval for Teva's Tolvaptan ANDA216933

Study on Thyroid Hormones in Severe CKD Stages G4-G5 Initiated

Exosomes in Renal Fibrosis: Dual Roles and Therapeutic Potential

Study on PIIINP and Urinary NGAL as Biomarkers for Renal Function Recovery

VExUS Protocol Study Aims to Improve Hemodialysis Patient Outcomes

Machine Learning Model Developed to Differentiate Diabetic Kidney Disease in Type 2 Diabetes

Phase I Trial of VC005 Tablets in Renal Impairment Shows Safety and Pharmacokinetics

Renibus Therapeutics initiates long-term study of Veverimer for CKD and metabolic acidosis

Akebia Therapeutics initiates Phase 2 trial of praliciguat for FSGS

Shionogi's S-892216 Study Targets Renal Impairment Pharmacokinetics

Novartis Fabhalta® (iptacopan) gains FDA approval for primary IgAN treatment

Otsuka initiates trial for Sibeprenlimab in IgA Nephropathy

Lactiplantibacillus plantarum WJL enhances low-protein diet efficacy in chronic kidney disease

Novartis initiates Phase III trial of Atrasentan in pediatric IgAN patients

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy

Study on Plasma Exchange vs. Daratumumab for Light Chain Cast Nephropathy

Nanotechnology Advances in Podocyte Injury Repair for Chronic Kidney Diseases

FDA Approves Trutakna for Proteinuria in Primary IgA Nephropathy

Study on AVA Use in Continuous Renal Replacement Therapy to Reduce Catheter Risks

Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients

FDA Accepts ANDA for Tolvaptan by Alkem Labs

Phase 1 Study of MTX-439 in Diabetic Kidney Disease Patients Initiated by Mediar Therapeutics

Trial on pHA130 Hemoadsorption in Kidney Failure Patients Shows Potential for Improved Outcomes

Boehringer Ingelheim Tests Vicadrostat with Empagliflozin in CKD Patients

Amino Acid Infusion Shows No Benefit for AKI Post-Aortic Surgery, Subgroup Suggests Potential in Older Patients

Study Evaluates Nephrotoxic Risks in CKD Patients Using SGLT2 Inhibitors

SP16 Trial Aims to Prevent Acute Kidney Injury in CKD Patients Undergoing Cardiac Surgery

Nalfurafine Hydrochloride Shows Promise for Treating Pruritus in Hemodialysis Patients

Pilot Trial of Low-Dose Colchicine in CKD Aims to Improve Vascular and Bone Outcomes

Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients

Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults

Ultomiris meets primary endpoint in Phase III trial for IgAN

FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE

Upcoming catalysts

Indications

Get signals before the market moves